The highlights of kidney transplantation in2023

Abstract

In 2023, significant advances were made in various areas of kidney transplantation. Firstly, the use of a balanced crystalloid solution in the recipient appears to prevent the delay in graft function, unlike hypothermia in the donor and normothermic pulsatile perfusion. Understanding the pathophysiology of humoral rejection has progressed, highlighting the major role of HLA class II molecules and innate immune cells (NK and monocytes expressing FCGR3A). An automatic Banff classification algorithm has been developed to better categorize biopsies in currently known diagnoses. CXCL10, combined with other variables, seems effective in ruling out rejection, but its role in routine care is yet to be defined. Regarding cytomegalovirus (CMV), letermovir has been proven effective in preventing CMV disease in D+R- patients, with fewer hematological side effects. For R+ patients, monitoring CMV-specific T-cell immunity is suggested to reduce the duration of antiviral prophylaxis. The only innovation in immunosuppression is imlifidase for highly sensitized patients, guided by French recommendations. A new equation for glomerular filtration rate measurement has been developed for kidney transplant recipients, performing well across various analyzed stratifications. Finally, xenotransplantation is making a comeback this year, generating hope. However, the description of early humoral rejections involving innate immune cells indicates that adjustments are still needed before considering its widespread deployment.